nodes	percent_of_prediction	percent_of_DWPC	metapath
Methoxsalen—CYP1A2—Sorafenib—thyroid cancer	0.117	0.369	CbGbCtD
Methoxsalen—CYP3A4—Vandetanib—thyroid cancer	0.101	0.321	CbGbCtD
Methoxsalen—Dermatitis acneiform—Vandetanib—thyroid cancer	0.069	0.101	CcSEcCtD
Methoxsalen—CYP3A4—Sorafenib—thyroid cancer	0.0612	0.193	CbGbCtD
Methoxsalen—Folliculitis—Vandetanib—thyroid cancer	0.0375	0.0549	CcSEcCtD
Methoxsalen—CYP3A4—Doxorubicin—thyroid cancer	0.0371	0.117	CbGbCtD
Methoxsalen—Folliculitis—Sorafenib—thyroid cancer	0.0253	0.037	CcSEcCtD
Methoxsalen—Dermatitis bullous—Vandetanib—thyroid cancer	0.0179	0.0262	CcSEcCtD
Methoxsalen—Dry skin—Vandetanib—thyroid cancer	0.0157	0.0229	CcSEcCtD
Methoxsalen—Skin exfoliation—Sorafenib—thyroid cancer	0.0152	0.0222	CcSEcCtD
Methoxsalen—Leukoderma—Epirubicin—thyroid cancer	0.0138	0.0202	CcSEcCtD
Methoxsalen—Photosensitivity reaction—Vandetanib—thyroid cancer	0.0135	0.0197	CcSEcCtD
Methoxsalen—Depression—Vandetanib—thyroid cancer	0.0131	0.0192	CcSEcCtD
Methoxsalen—Leukoderma—Doxorubicin—thyroid cancer	0.0128	0.0187	CcSEcCtD
Methoxsalen—Dry skin—Sorafenib—thyroid cancer	0.0106	0.0155	CcSEcCtD
Methoxsalen—Arrhythmia—Vandetanib—thyroid cancer	0.0106	0.0155	CcSEcCtD
Methoxsalen—Dysgeusia—Vandetanib—thyroid cancer	0.0101	0.0148	CcSEcCtD
Methoxsalen—Muscle spasms—Vandetanib—thyroid cancer	0.0099	0.0145	CcSEcCtD
Methoxsalen—Skin hyperpigmentation—Epirubicin—thyroid cancer	0.00988	0.0145	CcSEcCtD
Methoxsalen—Folliculitis—Epirubicin—thyroid cancer	0.00935	0.0137	CcSEcCtD
Methoxsalen—Skin hyperpigmentation—Doxorubicin—thyroid cancer	0.00914	0.0134	CcSEcCtD
Methoxsalen—Redness—Epirubicin—thyroid cancer	0.0087	0.0127	CcSEcCtD
Methoxsalen—Folliculitis—Doxorubicin—thyroid cancer	0.00865	0.0127	CcSEcCtD
Methoxsalen—Oedema—Vandetanib—thyroid cancer	0.00841	0.0123	CcSEcCtD
Methoxsalen—Infection—Vandetanib—thyroid cancer	0.00835	0.0122	CcSEcCtD
Methoxsalen—Skin disorder—Vandetanib—thyroid cancer	0.00817	0.0119	CcSEcCtD
Methoxsalen—Blister—Epirubicin—thyroid cancer	0.00815	0.0119	CcSEcCtD
Methoxsalen—Redness—Doxorubicin—thyroid cancer	0.00805	0.0118	CcSEcCtD
Methoxsalen—Insomnia—Vandetanib—thyroid cancer	0.0076	0.0111	CcSEcCtD
Methoxsalen—Blister—Doxorubicin—thyroid cancer	0.00754	0.011	CcSEcCtD
Methoxsalen—Dyspepsia—Vandetanib—thyroid cancer	0.0074	0.0108	CcSEcCtD
Methoxsalen—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00726	0.0106	CcSEcCtD
Methoxsalen—Arrhythmia—Sorafenib—thyroid cancer	0.00713	0.0104	CcSEcCtD
Methoxsalen—Erythema—Sorafenib—thyroid cancer	0.00695	0.0102	CcSEcCtD
Methoxsalen—Dysgeusia—Sorafenib—thyroid cancer	0.00681	0.00996	CcSEcCtD
Methoxsalen—Muscle spasms—Sorafenib—thyroid cancer	0.00668	0.00978	CcSEcCtD
Methoxsalen—Body temperature increased—Vandetanib—thyroid cancer	0.00665	0.00972	CcSEcCtD
Methoxsalen—Herpes simplex—Epirubicin—thyroid cancer	0.00638	0.00933	CcSEcCtD
Methoxsalen—Inflammation—Epirubicin—thyroid cancer	0.00606	0.00886	CcSEcCtD
Methoxsalen—Pruritus—Vandetanib—thyroid cancer	0.00595	0.0087	CcSEcCtD
Methoxsalen—Herpes simplex—Doxorubicin—thyroid cancer	0.0059	0.00863	CcSEcCtD
Methoxsalen—Infection—Sorafenib—thyroid cancer	0.00563	0.00824	CcSEcCtD
Methoxsalen—Skin exfoliation—Epirubicin—thyroid cancer	0.00561	0.00821	CcSEcCtD
Methoxsalen—Inflammation—Doxorubicin—thyroid cancer	0.0056	0.0082	CcSEcCtD
Methoxsalen—Dizziness—Vandetanib—thyroid cancer	0.00556	0.00813	CcSEcCtD
Methoxsalen—Skin disorder—Sorafenib—thyroid cancer	0.00551	0.00806	CcSEcCtD
Methoxsalen—Cramps of lower extremities—Epirubicin—thyroid cancer	0.0054	0.0079	CcSEcCtD
Methoxsalen—Rash—Vandetanib—thyroid cancer	0.0053	0.00776	CcSEcCtD
Methoxsalen—Dermatitis—Vandetanib—thyroid cancer	0.0053	0.00775	CcSEcCtD
Methoxsalen—Headache—Vandetanib—thyroid cancer	0.00527	0.00771	CcSEcCtD
Methoxsalen—Skin exfoliation—Doxorubicin—thyroid cancer	0.00519	0.00759	CcSEcCtD
Methoxsalen—Nausea—Vandetanib—thyroid cancer	0.00499	0.00731	CcSEcCtD
Methoxsalen—Cramps of lower extremities—Doxorubicin—thyroid cancer	0.00499	0.00731	CcSEcCtD
Methoxsalen—Dyspepsia—Sorafenib—thyroid cancer	0.00499	0.0073	CcSEcCtD
Methoxsalen—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.0049	0.00716	CcSEcCtD
Methoxsalen—Urticaria—Sorafenib—thyroid cancer	0.00451	0.00659	CcSEcCtD
Methoxsalen—Body temperature increased—Sorafenib—thyroid cancer	0.00448	0.00656	CcSEcCtD
Methoxsalen—Dermatitis bullous—Epirubicin—thyroid cancer	0.00446	0.00653	CcSEcCtD
Methoxsalen—Hypersensitivity—Sorafenib—thyroid cancer	0.00418	0.00611	CcSEcCtD
Methoxsalen—Dermatitis bullous—Doxorubicin—thyroid cancer	0.00413	0.00604	CcSEcCtD
Methoxsalen—Pruritus—Sorafenib—thyroid cancer	0.00401	0.00587	CcSEcCtD
Methoxsalen—Dry skin—Epirubicin—thyroid cancer	0.00391	0.00572	CcSEcCtD
Methoxsalen—Dizziness—Sorafenib—thyroid cancer	0.00375	0.00549	CcSEcCtD
Methoxsalen—Dry skin—Doxorubicin—thyroid cancer	0.00362	0.00529	CcSEcCtD
Methoxsalen—Rash—Sorafenib—thyroid cancer	0.00358	0.00523	CcSEcCtD
Methoxsalen—Dermatitis—Sorafenib—thyroid cancer	0.00357	0.00523	CcSEcCtD
Methoxsalen—Headache—Sorafenib—thyroid cancer	0.00355	0.0052	CcSEcCtD
Methoxsalen—Nausea—Sorafenib—thyroid cancer	0.00337	0.00493	CcSEcCtD
Methoxsalen—Photosensitivity reaction—Epirubicin—thyroid cancer	0.00336	0.00492	CcSEcCtD
Methoxsalen—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.00311	0.00455	CcSEcCtD
Methoxsalen—Arrhythmia—Epirubicin—thyroid cancer	0.00264	0.00386	CcSEcCtD
Methoxsalen—Erythema—Epirubicin—thyroid cancer	0.00257	0.00376	CcSEcCtD
Methoxsalen—Tension—Epirubicin—thyroid cancer	0.00252	0.00369	CcSEcCtD
Methoxsalen—Dysgeusia—Epirubicin—thyroid cancer	0.00252	0.00368	CcSEcCtD
Methoxsalen—Nervousness—Epirubicin—thyroid cancer	0.00249	0.00365	CcSEcCtD
Methoxsalen—Muscle spasms—Epirubicin—thyroid cancer	0.00247	0.00361	CcSEcCtD
Methoxsalen—Arrhythmia—Doxorubicin—thyroid cancer	0.00244	0.00357	CcSEcCtD
Methoxsalen—Ill-defined disorder—Epirubicin—thyroid cancer	0.00238	0.00349	CcSEcCtD
Methoxsalen—Erythema—Doxorubicin—thyroid cancer	0.00238	0.00348	CcSEcCtD
Methoxsalen—Tension—Doxorubicin—thyroid cancer	0.00233	0.00341	CcSEcCtD
Methoxsalen—Dysgeusia—Doxorubicin—thyroid cancer	0.00233	0.0034	CcSEcCtD
Methoxsalen—Malaise—Epirubicin—thyroid cancer	0.00232	0.00339	CcSEcCtD
Methoxsalen—Nervousness—Doxorubicin—thyroid cancer	0.00231	0.00338	CcSEcCtD
Methoxsalen—Vertigo—Epirubicin—thyroid cancer	0.00231	0.00338	CcSEcCtD
Methoxsalen—Muscle spasms—Doxorubicin—thyroid cancer	0.00228	0.00334	CcSEcCtD
Methoxsalen—Ill-defined disorder—Doxorubicin—thyroid cancer	0.0022	0.00323	CcSEcCtD
Methoxsalen—Discomfort—Epirubicin—thyroid cancer	0.00216	0.00316	CcSEcCtD
Methoxsalen—Malaise—Doxorubicin—thyroid cancer	0.00214	0.00314	CcSEcCtD
Methoxsalen—Vertigo—Doxorubicin—thyroid cancer	0.00214	0.00312	CcSEcCtD
Methoxsalen—Oedema—Epirubicin—thyroid cancer	0.0021	0.00307	CcSEcCtD
Methoxsalen—Infection—Epirubicin—thyroid cancer	0.00208	0.00305	CcSEcCtD
Methoxsalen—Skin disorder—Epirubicin—thyroid cancer	0.00204	0.00298	CcSEcCtD
Methoxsalen—Discomfort—Doxorubicin—thyroid cancer	0.002	0.00292	CcSEcCtD
Methoxsalen—Hypotension—Epirubicin—thyroid cancer	0.00196	0.00287	CcSEcCtD
Methoxsalen—Oedema—Doxorubicin—thyroid cancer	0.00194	0.00284	CcSEcCtD
Methoxsalen—Infection—Doxorubicin—thyroid cancer	0.00193	0.00282	CcSEcCtD
Methoxsalen—Insomnia—Epirubicin—thyroid cancer	0.0019	0.00277	CcSEcCtD
Methoxsalen—Skin disorder—Doxorubicin—thyroid cancer	0.00188	0.00276	CcSEcCtD
Methoxsalen—Dyspepsia—Epirubicin—thyroid cancer	0.00185	0.0027	CcSEcCtD
Methoxsalen—Hypotension—Doxorubicin—thyroid cancer	0.00181	0.00265	CcSEcCtD
Methoxsalen—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00181	0.00265	CcSEcCtD
Methoxsalen—Insomnia—Doxorubicin—thyroid cancer	0.00175	0.00257	CcSEcCtD
Methoxsalen—Feeling abnormal—Epirubicin—thyroid cancer	0.00173	0.00253	CcSEcCtD
Methoxsalen—Dyspepsia—Doxorubicin—thyroid cancer	0.00171	0.0025	CcSEcCtD
Methoxsalen—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.00167	0.00245	CcSEcCtD
Methoxsalen—Urticaria—Epirubicin—thyroid cancer	0.00167	0.00244	CcSEcCtD
Methoxsalen—Body temperature increased—Epirubicin—thyroid cancer	0.00166	0.00242	CcSEcCtD
Methoxsalen—Feeling abnormal—Doxorubicin—thyroid cancer	0.0016	0.00234	CcSEcCtD
Methoxsalen—Hypersensitivity—Epirubicin—thyroid cancer	0.00154	0.00226	CcSEcCtD
Methoxsalen—Urticaria—Doxorubicin—thyroid cancer	0.00154	0.00225	CcSEcCtD
Methoxsalen—Body temperature increased—Doxorubicin—thyroid cancer	0.00153	0.00224	CcSEcCtD
Methoxsalen—Pruritus—Epirubicin—thyroid cancer	0.00148	0.00217	CcSEcCtD
Methoxsalen—Hypersensitivity—Doxorubicin—thyroid cancer	0.00143	0.00209	CcSEcCtD
Methoxsalen—Dizziness—Epirubicin—thyroid cancer	0.00139	0.00203	CcSEcCtD
Methoxsalen—Pruritus—Doxorubicin—thyroid cancer	0.00137	0.00201	CcSEcCtD
Methoxsalen—Rash—Epirubicin—thyroid cancer	0.00132	0.00193	CcSEcCtD
Methoxsalen—Dermatitis—Epirubicin—thyroid cancer	0.00132	0.00193	CcSEcCtD
Methoxsalen—Headache—Epirubicin—thyroid cancer	0.00131	0.00192	CcSEcCtD
Methoxsalen—Dizziness—Doxorubicin—thyroid cancer	0.00128	0.00188	CcSEcCtD
Methoxsalen—Nausea—Epirubicin—thyroid cancer	0.00125	0.00182	CcSEcCtD
Methoxsalen—Rash—Doxorubicin—thyroid cancer	0.00122	0.00179	CcSEcCtD
Methoxsalen—Dermatitis—Doxorubicin—thyroid cancer	0.00122	0.00179	CcSEcCtD
Methoxsalen—Headache—Doxorubicin—thyroid cancer	0.00122	0.00178	CcSEcCtD
Methoxsalen—Nausea—Doxorubicin—thyroid cancer	0.00115	0.00169	CcSEcCtD
